Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Do Hedge Funds Love IntelliPharmaCeutics International Inc. (I)?

Page 1 of 2

Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ a complex analysis to determine the best stocks to invest in. A particularly interesting group of stocks that hedge funds like is the small-caps. The huge amount of capital does not allow hedge funds to invest a lot in small-caps, but our research showed that their most popular small-cap ideas are less efficiently priced and generate stronger returns than their large- and mega-cap picks and the broader market. That is why we follow the hedge fund activity in the small-cap space.

Intelsat SA. (NYSE:I) shares haven’t seen a lot of action during the third quarter. Overall, hedge fund sentiment was unchanged. The stock was in 11 hedge funds’ portfolios at the end of the third quarter of 2015. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity, but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Atrion Corporation (NASDAQ:ATRI), McGrath RentCorp (NASDAQ:MGRC), and DHT Holdings Inc (NYSE:DHT) to gather more data points.

Follow Intellipharmaceutics Intl Inc (NASDAQ:IPCI)
Trade (NASDAQ:IPCI) Now!

In the eyes of most stock holders, hedge funds are assumed to be worthless, outdated investment vehicles of years past. While there are more than 8000 funds in operation at present, Our researchers choose to focus on the masters of this club, about 700 funds. These investment experts manage most of the smart money’s total capital, and by tailing their finest investments, Insider Monkey has formulated numerous investment strategies that have historically exceeded the broader indices. Insider Monkey’s small-cap hedge fund strategy outstripped the S&P 500 index by 12 percentage points a year for a decade in their back tests.

Keeping this in mind, let’s take a gander at the recent action encompassing Intelsat SA (NYSE:I)

What does the smart money think about IntelliPharmaCeutics Intelsat SA (NYSE:I)?

At the Q3’s end, a total of 11 of the hedge funds tracked by Insider Monkey held long positions in this stock, unchanged from one quarter earlier. With hedgies’ capital changing hands, there exists a few key hedge fund managers who were upping their holdings substantially (or already accumulated large positions).

When looking at the institutional investors followed by Insider Monkey, Paul J. Isaac’s Arbiter Partners Capital Management has the largest position in Intelsat SA (NYSE:I), worth close to $29.1 million, amounting to 2.9% of its total 13F portfolio. Coming in second is Cyrus Capital Partners, managed by Stephen C. Freidheim, which holds a $10 million position; 1.1% of its 13F portfolio is allocated to the stock. Some other professional money managers that hold long positions contain D. E. Shaw’s D E Shaw, Kevin Michael Ulrich and Anthony Davis’ Anchorage Advisors, and Jim Simons’ Renaissance Technologies.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!